期刊文献+

分光光度法测定非布司他片的溶出度 被引量:1

Dissolution determination of Febuxostat tablets by UV Spectrophotography
下载PDF
导出
摘要 目的建立非布司他溶出度的测定方法。方法依照《中国药典》2005年版二部附录溶出度项下第二法,磷酸盐缓冲液(pH6.8)为溶出介质,转速为50r/min,紫外可见分光光度法测定,检测波长为315nm。结果在1.813~18.131g/mL范围内(r=1.000),浓度与吸光度呈良好的线性关系,平均回收率为99.93%,RSD为0.59%(n=9)。结论该法操作简便、准确可靠,可作为非布司他的质量控制方法。 Objective To establish the dissolution determination of Febuxostat Tablets with UV spectroph otography.Methods According to the 2005 editional appendix of The Pharmacopoeia of the PRC,phosphate buffer with pH=6.8 was the dissolution medium,and the scan wavelength was 315nm.Results The absorption was good linear in the concentraion range of 1.813~18.131 g/mL (r=1.000).The average recovery was 99.93%,RSD=0.59%(n=9).Conclusion The method is good,simple and accurate,which can be used as quality control method.
出处 《医学研究与教育》 CAS 2010年第5期8-10,共3页 Medical Research and Education
基金 国家自然科学基金资助项目(200511140231)
关键词 非布司他 溶出度 紫外可见分光光度法 Febuxostat dissolution UV Spectrophotography
  • 相关文献

参考文献4

二级参考文献5

共引文献9

同被引文献26

  • 1陈光亮,王琳琳,徐叔云.防治痛风的药物研究进展[J].国外医学(内分泌学分册),2005,25(4):277-279. 被引量:15
  • 2朱深银,周远大,杜冠华.防治痛风药物的研究进展[J].医药导报,2006,25(8):803-806. 被引量:31
  • 3Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 AmericanCollege of Rheumatology guidelines for management of gout. Part1: systematic on pharmacologic and pharmacologic therapeuticapproaches to hyperuricemia[J]. Arthritis Care Res (Hoboken),2012, 64(10): 1431-1446.
  • 4Okamoto K, Eger BT, Nishino T, et al. An extremely potentinhibitor of xanthine oxidoreductase. Crystal structure of theenzyme-inhibitorcomplex and mechanism of inhibition[J]. J BiolChem, 2003, 278(3): 1848-1855.
  • 5Canivet J, Yamaguchi J, Ban I,et a I. Nickel-catalyzed biarylcoupling of heteroarenes and arylhalides/triflates[J]. OrgLett, 2009,11(8): 1733-1736.
  • 6Komiyama M. Method for producing phenyl substitutedheterocyclic derivative by means of coupling method using apalladium compound[P]. WO 2012 026 565, 2012-03-01.
  • 7Khosravan R, Grabowski B, Wu JT, et al. Pharmacokinetics,pharmacodynamics and safety of fubuxostat, a non-purine selectiveinhibitor of xanthine oxidase, in a dose escalation study in healthysubjects[J]. Clin Pharmacokinet, 2006, 45: 821-841.
  • 8Khosravan R, Grabowski BA, Wu JT, et al. Effect of food or antacidon pharmacokinetics and pharmacodynamics of febuxostat inhealthy subjects[J]. Br J Clin Pharmacol, 2007, 65: 355-363.
  • 9Khosravan R, Grabowski B, Wu JT, et al Effect of food or antacidon pharmacokinetics and pharmacodynamics of febuxostat inhealthy subjects[J], Br J Clin Pharmacol, 2008, 65(3): 355-363.
  • 10Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, issafe and decreases serum urate in healthy volunteers. NucleosidesNucleotides Nucleic Acids, 2004,23(8-9): 1111-1116.

引证文献1

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部